Genetic Technologies Limited · ASX:GTG
Genetic Technologies — HC Wainwright & Co BioConnect 2021 Conference
17 slides from Genetic Technologies's conference presentation, Jan 12, 2021
Slide 1: Genetic based preventative health platform
For personal use only Genetic based preventative health platform NASDAQ: GENE HC Wainwright & Co BioConnect 2021 Conference 11-14 January 2021 In Market Authorised by the Board of Genetic Technologies Coming soon
Slide 2: Notice: Forward looking statements
Notice: Forward looking statements For personal use only The purpose of the presentation is to provide an update of the business of Genetic Technologies Limited ACN: 009 212 328 (ASX:GTG; NASDAQ:GENE). These slides have been prepared as a presentation aid only and the information they contain may re
Slide 3: Genetic Technologies - Leader in Genomics
Genetic Technologies - Leader in Genomics For personal use only Publications and academic Strong focus on R&D Robust patent portfolio collaborations Over a decade of R&D on the 15 patents granted and 7 patent Two peer-reviewed publications and four development of polygenic risk scores families pendi
Slide 4: Product Overview
Product Overview For personal use only Released 2019/2020 Germline Products Under Development Colorectal Cancer Breast Cancer BRCA Panel Lynch Syndrome PRS Products Under Development COVID-19 Depression Type 2 Diabetes Prostate Cancer Melanoma Cardiovascular (PREDICTIX by Taliaz) Disease 4
Slide 5: Significant market opportunity
Significant market opportunity For personal use only GTG aims to provide predictive, pre-symptomatic testing to inform lifestyle choices and healthcare discussions Near Term Addressable Market GTG Target Market for BRCA Panel + Breast Cancer PRS Testing providing up to 100% genetic 275,000 1st degre
Slide 6: Responding to unique opportunities and challenges
Responding to unique opportunities and challenges For personal use only Genetype for COVID-19 SDR Test - World first genetic risk test that predicts your risk of hospitalisation & life threatening complications Highlights Product Overview • Rapid response and creation of the test • Simple oral swab
Slide 7: Partnership to provide expanded product offering
Partnership to provide expanded product offering For personal use only Genetype for Depression - Powered by Taliaz’s PREDICTIX platform Highlights Product Overview • Key opportunity with strong product alignment to integrate into our • Utilising a combination of: platform in line with our mandate to
Slide 8: Expanding divisions and product offerings
Expanding divisions and product offerings For personal use only ONCOLOGY Lifestyle Ancestry BC, CRC, PC, /Microbiome Melanoma GENETIC TECHNOLOGIES CVD (Genetype) Pharmoco- (Heart Disease) genetics IHD, AF Mental Metabolic Health Diseases (by Taliaz) Diabetes Germline COVID-19 Testing SDR (BRCA, Lync
Slide 9: Regional Distribution
Regional Distribution For personal use only United States Australia Europe • Certification by US regulators CLIA to sell • Certification by Australian regulators NATA, to • Looking to commence CE certification with into the USA sell into the Australian market the view of entering the European market
Slide 10: Sales platforms and methods
Sales platforms and methods For personal use only • Third Party Licensing • Provides enhanced distribution and product offering via: • Licensing of own products for enhanced distribution opportunities (ie. COVID-19 distribution opportunities with US labs) • Licensing of novel products for enhanced p
Slide 11: Outlook
Outlook For personal use only 1H1H CY21 CY20 2H CY21 and beyond COVID-19 SDR Test High Density/Multitest Market Release to include the following: • Breast Cancer • Colorectal Cancer Germline Testing • Cardiovascular Disease • Type 2 Diabetes BRCA/Lynch Syndrome • Melanoma • Prostate Cancer • COVID-1
Slide 12: Strategy
Strategy For personal use only • GTG have now established a clear product pipeline and direction: • Transitioned from one product two years ago to 10 products in development • Ability to accelerate the development of new products and tests • Expanding into reimbursable space • Focused on: • Establis
Slide 13: Thank You
For personal use only Thank You
Slide 14: Appendices
For personal use only Appendices
Slide 15: Corporate Overview
Corporate Overview For personal use only Top 50 share registry breakdown Dual Listed on the ASX and Nasdaq 21% Financial Information Bank of Melon (Custodian for US ADRs) Share price (AUD) as at 5 January 2021 0.9c ADR price (USD) as at 5 January 2021 $4.02 7% Board and Management Ord Share on Issue
Slide 16: Our board
Our board For personal use only Dr. Jerzy “George” Muchnicki Dr. Lindsay Wakefield MBBS MBBS Executive Director & Chief Executive Officer (Interim) Non – Executive Director Mr. Peter Rubinstein Mr Nick Burrows B.Com, FAICD, FCA, FGIA, FTIA, F Fin BSc, BEc, LLB Non – Executive Director Chairman - Non
Slide 17: Defined Terms
Defined Terms For personal use only Common Complex Diseases (CCP) – A complex disease is caused by the interaction of multiple genes and environmental factors. Complex diseases are also called multifactorial. Examples of common complex diseases include cancer and heart disease. Polygenic Risk Score
Genetic Technologies — HC Wainwright & Co BioConnect 2021 Conference on 6ix